Predictive value and changes of miR‑34a after concurrent chemoradiotherapy and its association with cognitive function in patients with nasopharyngeal carcinoma
- Weiyu Deng
- Anqi Lin
- Jialin Yang
Affiliations: Department of Neurology, Shunde Hospital, Guangzhou University of Traditional Chinese Medicine, Foshan, Guangdong 528300, P.R. China, Department of Pneumology, Shunde Hospital, Guangzhou University of Traditional Chinese Medicine, Foshan, Guangdong 528300, P.R. China, Department of Oncology, Shunde Hospital, Guangzhou University of Traditional Chinese Medicine, Foshan, Guangdong 528300, P.R. China
- Published online on: August 20, 2020 https://doi.org/10.3892/ol.2020.11995
Copyright: © Deng
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
This study explored the changes and predictive value of miR‑34a in nasopharyngeal carcinoma (NPC) after concurrent chemoradiotherapy (CCRT), and its association with cognitive function. Fifty NPC patients admitted to Shunde Hospital, and another fifty healthy individuals were assigned into treated group and control group, respectively. Patients in the treated group received 3 courses of CCRT. The relative expression of miR‑34a in the two groups was detected, and the cognitive function of patients was assessed. Diagnostic and predictive values of miR‑34a in advanced NPC were analyzed. The expression of miR‑34a in the control group was significantly higher than that in the treated group (t=13.364, P<0.001), with an area under the curve (AUC) of 0.979. The expression of miR‑34a was significantly upregulated after treatment (t=4.559, P<0.001). After treatment, there were 32 complete remission (CR) patients and 18 partial remission (PR) patients. According to efficacy, CR patients were classified as significant group and PR patients as general group. The expression of miR‑34a in the significant group was higher than that in the general group before treatment (t=4.704, P<0.001), with an AUC of 0.852. The Montreal Cognitive Assessment (MoCA) score was significantly decreased after treatment (t=13.042, P<0.001). The expression of miR‑34a was positively correlated with the MoCA score after treatment, that is, MoCA score gradually increased with the upregulation of miR‑34a expression (r=0.379, P=0.006). There is a positive correlation between miR‑34a and cognitive function of patients. Moreover, the expression of miR‑34a can be used as a potential predictor of the efficacy of CCRT in patients with NPC.